Inclusion Criteria:

1. Patients age 18 years or more.
2. Histologically confirmed diagnosis of non-small-cell lung carcinoma.
3. Only patients with advanced disease, defined as stage IV or IIIB with/without pleural effusion, will be included.
4. Tumor sample available (minimum of three 5-µm slices or tumor area 5-7 mm2).
5. A measurable lesion, as defined by RECIST criteria.
6. Karnofsky score 60% or more (ECOG<2).
7. Patients should not have received previous treatment with chemotherapy or other agents for disseminated disease. Chemotherapy is allowed if the initial diagnosis of the patient is limited disease and the patient has received adjuvant or neoadjuvant treatment.
8. Patients with cerebral disease are permitted, without any time limitations after holocranial irradiation or complementary antiedema treatment.

9. Patients with the following hematologic values:

   ANC >= 1.5 x 109/L Hb >= 10 g/dl Platelets ³ 100 x 109/L

10. Patients with the following biochemical values:

    Bilirubin <= 1.0 mg/dL AST and ALT < 1.5 upper limit of normality Creatinine clearance >= 60 ml/min.

11. Patients of childbearing age of either sex must use effective contraceptive methods (barrier methods or other birth control methods) before entering the study and while participating in the study.
12. Patients should sign an informed consent form before inclusion in the study that specifies that the clinical trial treatment entails consent for the analysis of biological samples of tumor and blood.
13. Patients must be available for clinical follow-up.

Exclusion Criteria:

1. Previous chemotherapy treatment.
2. Patients diagnosed of another neoplasm, with the exception of cervix carcinoma in situ, treated squamous cell carcinomas or superficial bladder tumors (Ta and TIS), or other malignant tumors that have received curative treatment at least 5 years before inclusion in the study.
3. Patients with active bacterial or fungal infective processes qualified clinically as serious (>= grade 2 of NCI-CTC, Version 3).
4. Patients who have received an investigational medicinal product in the 21 days before inclusion in the study.
5. Patients with HIV infection, HCV infection, uncontrolled coronary disease or arrhythmia, uncontrolled cerebrovascular disease and other clinical conditions that, in the judgment of the investigator, contraindicate the patient's participation in the study.
6. Patients who are pregnant or breastfeeding. Women of childbearing age must have a negative pregnancy test performed within 7 days before the onset of treatment.
7. Substance abuse, clinical, psychological or social conditions that can undermine the validity of the informed consent or protocol compliance.
8. Patients who present any contraindication or suspected allergy to the products under investigation in the study
9. Impossibility to comply with chemotherapy treatment due to cultural or geographic circumstances.
10. Significant weight loss (>= 10% of body weight) in the 6 weeks before inclusion in the study.
11. Any condition that is unstable or could endanger the patient's safety and/or the patient's compliance with the study.
12. Contraindication for steroid use.